Author:
Zeng Zhiyong,Lin Junfang,Chen Junmin
Publisher
Springer Science and Business Media LLC
Subject
Hematology,General Medicine
Reference23 articles.
1. Richardson PG (2004) A review of the proteasome inhibitor bortezomib in multiple myeloma. Expert Opin Pharmacother 5:1321–1331
2. Mateos MV, San Miguel JF (2007) Bortezomib in multiple myeloma. Best Pract Res Clin Haematol 20:701–715
3. Anderson KC, Anderson M, Bensinger W, Biermann JS, National Comprehensive Cancer Network (2009) Clinical practice guidelines in oncology—multiple myeloma (version 2.2009). http://www.nccn.org/professionals/physician_gls/PDF/myeloma.pdf . Accessed 20 Mar 2009
4. Curran MP, McKeage K (2009) Bortezomib: a review of its use in patients with multiple myeloma. Drugs 69:859–888
5. Mitsiades N, Mitsiades CS, Richardson PG, Poulaki V, Tai YT, Chauhan D, Fanourakis G, Gu X, Bailey C, Joseph M, Libermann TA, Schlossman R, Munshi NC, Hideshima T, Anderson KC (2003) The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 101:2377–2380
Cited by
20 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献